FDAnews
www.fdanews.com/articles/176929-avant-diagnostics-completes-acquisition-of-amarantus-diagnostics

Avant Diagnostics Completes Acquisition of Amarantus Diagnostics

June 6, 2016

Avant Diagnostics has completed its acquisition of San Francisco, Calif.-based Amarantus BioScience unit Amarantus Diagnostics valued at $25.6 million.

Amarantus specializes in the development of treatments and diagnostics for diseases in the fields of neurology, regenerative medicine and orphan diseases.

Company President and CEO Gerald E. Commissiong says Amarantus will now be investing the majority of its resources on the clinical development of the Engineered Skin Substitute program for the treatment of severe burns. — Michael Cipriano

View today's stories